AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
CVS Group Shares Rise Despite Intrinsic Value Gap
September 10, 2024 07:47 PM AEST| By Team Kalkine MediaCVS Group plc, operating within the,healthcare sector,, has recently experienced a notable increase in its share price, rising over 10% on the AIM market in the past few months. Despite this positive movement, the company's stock has traded at higher...
Futura Posts Early Maiden Profit, Revenue and Earnings to Surge
September 10, 2024 06:44 PM AEST| By Team Kalkine MediaFutura Medical PLC,(LSE:FUM),has announced a significant milestone in its financial performance for the first half of 2024, marking its first profit of £1 million on revenues of £7 million. The company closed the period with a strong balance sheet, h...
Futura Medical Hits Milestone with First Profit, Prepares for US Eroxon Launch
September 10, 2024 06:42 PM AEST| By Team Kalkine MediaFutura Medical PLC (LSE:FUM) CEO James Barder recently discussed the company's latest financial performance and future outlook with Proactive's Stephen Gunnion. Barder highlighted that Futura Medical has raised its guidance for both profit and revenu...
hVIVO CEO Highlights Record H1 Revenue and Strategic Expansion
September 10, 2024 06:17 PM AEST| By Team Kalkine MediahVIVO PLC,(LSE:HVO),CEO Yamin (Mo) Khan recently discussed the company’s notable achievements in the first half of 2024 with Proactive's Stephen Gunnion. During this period, hVIVO reported a 31% increase in revenue, reaching £35.6 million. Khan highl...
ImmuPharma reports interim progress on lead asset
September 10, 2024 04:41 AM AEST| By Team Kalkine MediaImmuPharma PLC,(LSE:IMM),has reported progress in developing treatments for autoimmune diseases, with a focus on Systemic Lupus Erythematosus (SLE) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). In its recent update accompanying its in...
Hutchmed to Present New and Updated Clinical Trial Data
September 09, 2024 10:27 PM AEST| By Team Kalkine MediaHutchmed China,(LSE:HCM),has announced that it will present new and updated clinical trial data at two major oncology conferences: the 2024 World Conference on Lung Cancer (WCLC24) in San Diego and the European Society for Medical Oncology (ESMO) Con...
RUA Life Sciences Acquires French Implantable Devices Company
September 09, 2024 09:10 PM AEST| By Team Kalkine MediaRUA Life Sciences,(LSE:RUA),has completed the acquisition of implantable devices manufacturer Analytic Biosurgical Solutions for €80,000. The purchase was made from the French liquidator of IPSA SAS, the former parent company of Analytic Biosurgical...
Oncimmune Shares Surge Following Contract Wins
September 09, 2024 08:32 PM AEST| By Team Kalkine MediaShares in Oncimmune, a company specializing in autoantibody profiling, saw a significant rise on Monday after the firm reported strong commercial progress since its last update in May.,Oncimmune announced that it had secured a major new project with...
Hemogenyx Pharmaceuticals Reaches Critical Milestone
September 09, 2024 04:50 PM AEST| By Team Kalkine MediaA prominent player of,Healthcare Sector,Hemogenyx Pharmaceuticals PLC has announced the successful development of a clinical-grade assay designed to measure FLT3 protein levels in acute myeloid leukaemia (AML) cells. This assay is a crucial component...
GSK Reports Positive Results from COPD Trial
September 06, 2024 08:54 PM AEST| By Team Kalkine MediaOn Friday, GSK,(LSE:GSK),reported positive results from its phase three ‘MATINEE’ clinical trial, which assessed the efficacy of ‘Nucala’ (mepolizumab) in treating chronic obstructive pulmonary disease (COPD). The FTSE 100 pharmaceutical company reve...
GSK Reports Positive COPD Trial Results
September 06, 2024 05:47 PM AEST| By Team Kalkine MediaSuccessful MATINEE Trial Results,GSK PLC,(LSE:GSK),has announced encouraging results from the Phase III clinical trial named MATINEE, which assessed the efficacy of Nucala (mepolizumab) in treating chronic obstructive pulmonary disease (COPD). The tr...
-Copy_09_04_2024_16_34_00_022161.jpg)
Indivior’s CUD Study Falls Short of Primary and Secondary Endpoints
September 05, 2024 02:29 AM AEST| By Team Kalkine MediaOn Wednesday, Indivior,(LSE:INDV),reported that the Phase 2B clinical trial conducted by Aelis Farma on the drug AEF0117 for treating cannabis use disorder (CUD) did not achieve its primary and secondary endpoints. The trial was designed with two key...
-Copy_09_03_2024_14_56_33_467030.jpg)
Aptamer Renews Contract with Unilever
September 04, 2024 12:55 AM AEST| By Team Kalkine MediaOn Tuesday, Aptamer,(LSE:APTA),, a company specializing in custom antibody alternatives, announced the extension of its contract with Unilever to advance the development of its Optimer asset for deodorant applications. This renewed agreement marks a...
Oxford Nanopore Shows Steady First Half Amid Market Challenges
September 03, 2024 08:54 PM AEST| By Team Kalkine MediaOn Tuesday, Oxford Nanopore Technologies,(LSE:ONT),reported a steady performance for the first half of the year, despite facing challenging market conditions. For the six months ending June 30, the London-listed company's revenue reached £84.1 millio...
Aptamer Group Gains Boost from Unilever Collaboration Extension
September 03, 2024 08:21 PM AEST| By Team Kalkine MediaShares of Aptamer Group PLC,(LSE:APTA),saw a 4% increase following the announcement of an extended contract with consumer giant Unilever PLC. The partnership focuses on advancing the development of Aptamer's Optimer binders, which are being designed...
Uniphar reports first-half growth in all its divisions
September 03, 2024 06:35 PM AEST| By Team Kalkine MediaOn Tuesday, Uniphar,(LSE:UPR),, an international diversified healthcare service provider, reported robust first-half financial results, showcasing significant growth across all its divisions.,The AIM-traded company saw its revenue increase by 10.3%,...
Berenberg upgrades Hikma Pharmaceuticals
September 03, 2024 06:13 PM AEST| By Team Kalkine MediaOn Tuesday, Berenberg upgraded Hikma Pharmaceuticals,(LSE:HIK),, raising the price target from 2,100p to 2,400p, citing significant progress within the company. After nearly two years of maintaining a neutral stance, Berenberg now sees it as an oppor...
Futura Medical Soars as Eroxon Launches in US Stores and Online in October
September 02, 2024 10:58 PM AEST| By Team Kalkine MediaFutura Medical PLC,(LSE:FUM),has provided additional details regarding the US launch of its innovative erectile dysfunction gel, Eroxon, in collaboration with its major partner, Haleon PLC. As of September 1, the gel is available for pre-order online...
Roquefort Therapeutics Secures European Patent for MK Cell Therapy
September 02, 2024 10:38 PM AEST| By Team Kalkine MediaRoquefort Therapeutics PLC, a company operating within the,Healthcare sector,, has achieved a significant milestone with the European Patent Office granting a patent for its Mesodermal Killer (MK) cell therapy. This patent provides intellectual prope...
Oncimmune Wins New Contract with Top Ten Global Pharma Company
September 02, 2024 10:14 PM AEST| By Team Kalkine MediaOncimmune,(LSE:ONC),, a biotechnology firm, revealed on Monday that it has secured a significant new contract with a leading global pharmaceutical company, worth $700,000. This contract marks another step in the company's expansion and solidifies its...
AI on the Rise: A Look at Top AI Companies and Their Stocks